Biologics manufacturing seen topping $102B by 2030

The Business Research Company projects the global biologics manufacturing market will pass $102 billion by 2030, driven by outsourcing, biosimilars, cell and gene therapies, and rising demand for complex drugs. North America is expected to lead, while contract manufacturing remains the biggest segment.

Why it matters: - Biologics manufacturing is becoming a bigger part of the pharmaceuticals market as demand rises for advanced therapies that are harder to make at scale. - The market’s growth reflects broader pressure on drugmakers to add capacity, use more flexible production systems and speed commercialization. - The shift is also strengthening contract development and manufacturing organizations, which are taking on more of the production load.

What happened: - The Business Research Company projected the global biologics manufacturing market will exceed $102 billion by 2030. - The firm said the broader pharmaceuticals market will reach $2,496 billion by 2030. - North America is projected to be the largest regional market at $40 billion in 2030, up from $17 billion in 2025. - The USA is forecast to be the single biggest country market at $38 billion in 2030, up from $16 billion in 2025. - The market is expected to grow at a 19% compound annual growth rate through 2030. - Contract manufacturing is projected to be the largest manufacturing mode, at 69% of the market, or $71 billion, by 2030.

The details: - Growth in North America is being driven by large-scale biomanufacturing facilities, single-use bioreactors, outsourcing to CDMOs, monoclonal antibodies, cell and gene therapies, recombinant proteins, faster regulatory approvals, next-generation bioprocessing investments and demand for high-purity biologics. - US growth is tied to advanced bioprocess intensification, perfusion systems, new biomanufacturing hubs, onshore production and upgraded GMP-compliant infrastructure. - The report breaks the market into modalities including monoclonal antibodies, biosimilars and recombinant proteins, vaccines, cell and gene therapies, and RNA-based therapeutics. - It also segments demand by oncology, autoimmune disease, infectious disease, neurological disorders and other conditions. - The most promising growth opportunities are in contract manufacturing and in-house manufacturing, which together are expected to generate more than $60 billion by 2030. - Contract manufacturing is projected to expand by $45 billion from 2025 to 2030, while in-house manufacturing is expected to grow by $15 billion. - Samsung Biologics Co. Ltd. held 6% of global sales in 2025, according to the report. - Samsung Biologics’ CDMO services include cell line development, upstream and downstream bioprocessing, large-scale manufacturing and fill-finish support. - The company’s portfolio covers monoclonal antibodies, recombinant proteins and other complex biologics. - The top 10 firms accounted for 23% of revenue in 2025, showing a moderately fragmented market. - The market faces high barriers to entry, including GMP standards, validation demands, high capital needs and the need for scalable quality production. - A cited trend in October 2025 saw Samsung Biologics launch its ExellenS manufacturing framework, which standardizes facility designs, equipment and processes. - The framework is intended to improve consistency, predictability and regulatory approval timelines for biologic drugs.

Between the lines: - The report points to a market where scale and standardization matter as much as scientific innovation. - Outsourcing remains central because biologic drugs are becoming more complex, while manufacturers are under pressure to lower costs and improve speed. - Biosimilars and patent expirations are adding volume to the market, since companies are building cheaper production capacity and governments are pushing for broader access. - Personalized medicine is creating demand for modular, flexible and small-batch manufacturing, which favors firms with advanced process technology. - Competitive advantage appears to be shifting toward companies that can combine capacity, automation, continuous manufacturing and rapid technology transfer.

What's next: - The market is likely to keep expanding as oncology, immunology, cell therapy, gene therapy and biosimilar pipelines mature. - Drugmakers and CDMOs are expected to keep investing in single-use systems, continuous manufacturing platforms and automated monitoring tools. - Supply chain localization and resilience will likely remain a priority as companies expand capacity and diversify manufacturing footprints. - The report says the competitive landscape will stay active as major players deepen partnerships and add infrastructure worldwide.

The bottom line: - Biologics manufacturing is moving from a specialized niche to a core pharmaceutical growth engine, with contract manufacturing and advanced therapies leading the way.